Jessica Fye
Stock Analyst at JP Morgan
(3.82)
# 542
Out of 4,814 analysts
178
Total ratings
52.21%
Success rate
5.75%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Maintains: Overweight | $54 → $50 | $28.54 | +75.19% | 5 | Apr 14, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $29 → $28 | $15.56 | +79.95% | 4 | Apr 10, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $47 → $45 | $28.32 | +58.90% | 4 | Mar 24, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Overweight | $280 → $328 | $234.75 | +39.72% | 5 | Mar 24, 2025 | |
| MRNA Moderna | Maintains: Underweight | $40 → $33 | $24.73 | +33.47% | 12 | Mar 21, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $168 → $200 | $160.53 | +24.59% | 10 | Mar 18, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $200 → $209 | $102.02 | +104.86% | 4 | Feb 26, 2025 | |
| INSM Insmed | Maintains: Overweight | $83 → $92 | $72.47 | +26.95% | 7 | Feb 7, 2025 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $28 → $24 | $12.72 | +88.68% | 5 | Jan 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $503 → $500 | $489.10 | +2.23% | 7 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $124 → $122 | $98.76 | +23.53% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $109 | $59.12 | +84.37% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $71 | $58.22 | +21.95% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $27.05 | -3.88% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.63 | +293.18% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $52 → $57 | $58.66 | -2.83% | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $30.40 | +77.63% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $38.63 | +0.96% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $300 | $284.73 | +5.36% | 14 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $7.71 | +68.61% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.64 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $4.61 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $0.96 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $9.24 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $10 | $7.39 | +35.32% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $32.77 | +131.92% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.49 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.31 | +1,579.39% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.51 | +1,272.28% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $29.10 | -7.22% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.35 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.00 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.55 | - | 4 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.13 | - | 1 | Feb 8, 2018 |
Immunocore Holdings
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $28.54
Upside: +75.19%
NovoCure
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $15.56
Upside: +79.95%
Ionis Pharmaceuticals
Mar 24, 2025
Maintains: Neutral
Price Target: $47 → $45
Current: $28.32
Upside: +58.90%
Alnylam Pharmaceuticals
Mar 24, 2025
Upgrades: Overweight
Price Target: $280 → $328
Current: $234.75
Upside: +39.72%
Moderna
Mar 21, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $24.73
Upside: +33.47%
Ascendis Pharma
Mar 18, 2025
Maintains: Overweight
Price Target: $168 → $200
Current: $160.53
Upside: +24.59%
Jazz Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $102.02
Upside: +104.86%
Insmed
Feb 7, 2025
Maintains: Overweight
Price Target: $83 → $92
Current: $72.47
Upside: +26.95%
Denali Therapeutics
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $12.72
Upside: +88.68%
Vertex Pharmaceuticals
Dec 23, 2024
Maintains: Overweight
Price Target: $503 → $500
Current: $489.10
Upside: +2.23%
Nov 26, 2024
Maintains: Neutral
Price Target: $124 → $122
Current: $98.76
Upside: +23.53%
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $59.12
Upside: +84.37%
Oct 30, 2024
Maintains: Neutral
Price Target: $65 → $71
Current: $58.22
Upside: +21.95%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $27.05
Upside: -3.88%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $7.63
Upside: +293.18%
Sep 19, 2024
Downgrades: Neutral
Price Target: $52 → $57
Current: $58.66
Upside: -2.83%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $30.40
Upside: +77.63%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $38.63
Upside: +0.96%
May 21, 2024
Maintains: Overweight
Price Target: $280 → $300
Current: $284.73
Upside: +5.36%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $7.71
Upside: +68.61%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.64
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $4.61
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $0.96
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $9.24
Upside: -
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $7.39
Upside: +35.32%
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $32.77
Upside: +131.92%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.49
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.31
Upside: +1,579.39%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.51
Upside: +1,272.28%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $29.10
Upside: -7.22%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.35
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.00
Upside: -
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $8.55
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $5.13
Upside: -